Research use onlyFor laboratory and research purposes only — not for human consumption, medical, veterinary or diagnostic use.

PeptideStacks

Research peptide stacks — full directory

20 curated research peptide combinations, each documented with the underlying mechanism of action, summarised published studies, a complete dosing protocol, weekly timeline matrix, safety profile and UK regulatory note. All content is for laboratory and in vitro research use only.

How peptide stacks are organised on this site

A peptide stack in the published research literature is a combination of two or more research peptides administered concurrently or in deliberate sequence to address overlapping or complementary mechanisms. For example, the canonical BPC-157 + TB-500 healing stack covers two time-separated phases of the wound-repair cascade — BPC-157 for early angiogenesis, TB-500 for later cellular migration and remodelling. Stacking is not synonymous with "more peptides means more effect"; the published evidence supports stacking only where each compound contributes a distinct mechanism.

We group stacks by primary research goal because the underlying biology — not the marketing claim — determines what combinations make scientific sense. The 12 categories below map directly onto the major research areas in the 2024–2026 peptide literature:

  • Healing & tissue repair — soft tissue, tendon, ligament, gut and dermal repair. The most-studied category, with 2 stacks on this site. Anchored by the Sikiric-lab body of work on BPC-157 and the Bock-Marquette / Goldstein lab work on Thymosin β4 / TB-500. See our citation map of the Sikiric lab body of work.
  • Longevity & anti-ageing — telomerase, mitochondrial unfolded protein response, mitochondrial-metabolic. 3 stacks. Anchored by Khavinson-group bioregulators (Epitalon, Thymalin) and Cohen-lab mitochondrial-derived peptides (Humanin, MOTS-c). See Khavinson Bioregulators — the Soviet Peptide Tradition.
  • Nootropic & cognitive — BDNF up-regulation, GABAergic anxiolysis, pineal neuroprotection. 2 stacks. Anchored by Russian-origin neuropeptides (Semax, Selank) and porcine-brain neurotrophic preparations (Cerebrolysin).
  • Metabolic & fat-loss — GLP-1, GIP, glucagon and lipolytic peptides. 3 stacks. The largest growth area in the 2024–2026 literature, anchored by Tirzepatide, Retatrutide and the GH-fragment AOD-9604. See GLP-1 / GIP / Glucagon Triple Agonists and GLP-1 Receptor Biology Explained — From Exendin to Retatrutide.
  • Recovery, growth-hormone axis & body composition — synergistic GHRH + GHRP pairs (CJC-1295 + Ipamorelin), sustained GHRH analogues (Tesamorelin), and combinations with BPC-157 for connective-tissue protection.
  • Gut, immune & mucosal — anti-inflammatory and antimicrobial peptide combinations (KPV, LL-37, Thymosin α-1).
  • Sleep, libido, pigmentation, cardio & hair — single-axis research stacks covering specific physiological systems.

What every stack page contains

Every stack page on PeptideStacks.co.uk follows the same evidence-led structure so you can compare protocols head-to-head:

  1. An "in short" TL;DR block summarising the combination in 60–80 words.
  2. Mechanism of action for each peptide in the stack, referenced to the original discovery / characterisation papers.
  3. Summarised studies on the combination specifically — not just the individual peptides — with inline PubMed citations.
  4. The full research dosing table — dose, frequency, route, timing, cycle length.
  5. A weekly timeline matrix showing exactly what's administered when.
  6. Safety profile and UK MHRA regulatory note.
  7. Frequently asked research questions.
  8. A complete reference list with PubMed and DOI links.
  9. Where to source research-grade peptides for the stack (cross-link to PeptideBarn.co.uk) and where to read the full per-peptide research monograph (cross-link to PeptideAuthority.co.uk).

Difficulty bands explained

We classify stacks by research-handling difficulty rather than physiological "intensity":

  • Beginner — two peptides with straightforward subcutaneous administration, well-characterised dosing ranges, low side-effect profile in published research. Example: BPC-157 + TB-500.
  • Intermediate — multiple peptides or mixed routes (SC + IN + IM), titration required, or moderate side-effect profile. Example: CJC-1295 + Ipamorelin + Tesamorelin.
  • Advanced — complex protocols requiring close monitoring, dose escalation, or compounds with documented clinical-trial complications. Example: Tirzepatide + Retatrutide + AOD-9604.

UK regulatory reminder: all peptides discussed are unapproved research compounds in the UK unless explicitly noted otherwise. Tirzepatide (Mounjaro) is a licensed medicinal product; Tesamorelin (EGRIFTA) is FDA-approved with limited UK availability; everything else is for in vitro laboratory research only. See our MHRA / FDA / EMA peptide regulatory comparison and the full research disclaimer.

Loading stacks…